Tjalma W, Weyler J, Goovaerts G, De Pooter C, Van Marck E, van Dam P
Laboratory of Cancer Research and Clinical Oncology, University of Antwerp, Belgium.
J Clin Pathol. 1997 Jan;50(1):33-6. doi: 10.1136/jcp.50.1.33.
To evaluate the patterns of bcl-2 expression in early stage cervical carcinoma; to compare bcl-2 expression with clinicopathological findings; and to assess its prognostic value.
Wertheim radical hysterectomy specimens from 76 patients (FIGO stages Ia-IIb) with untreated nonmetastatic invasive cervical carcinoma were studied. Expression of bcl-2 was detected immunohistochemically using a monoclonal antibody. A tumour was regarded as positive when more than 5% of the neoplastic cells exhibited bcl-2 immunoreactivity.
Forty eight (63%) cervical carcinomas were scored as bcl-2 positive and 28 (37%) as bcl-2 negative. Most tumours showed heterogeneous cytoplasmic staining. Bc1-2 immunoreactivity did not correlate with tumour histology, tumour stage, presence of lymph node metastases, or involvement of the lymphovascular space. The five year survival rate for patients with bc1-2 negative tumours was 34% and was 71% for patients with bc1-2 positive tumours. On multiple regression analysis (Cox proportional hazards model), bc1-2 expression and vascular permeation were independent predictors of overall survival.
Bcl-2 expression seems to be associated with less aggressive behaviour in early stage cervical carcinoma. The transition to bcl-2 independence may play an important role in tumour progression.
评估早期宫颈癌中bcl-2的表达模式；比较bcl-2表达与临床病理特征；并评估其预后价值。
研究了76例未经治疗的非转移性浸润性宫颈癌患者（国际妇产科联盟分期Ia-IIb期）的韦特海姆根治性子宫切除术标本。使用单克隆抗体通过免疫组织化学检测bcl-2的表达。当超过5%的肿瘤细胞表现出bcl-2免疫反应性时，肿瘤被视为阳性。
48例（63%）宫颈癌bcl-2阳性，28例（37%）bcl-2阴性。大多数肿瘤表现出异质性细胞质染色。Bc1-2免疫反应性与肿瘤组织学、肿瘤分期、淋巴结转移的存在或淋巴管间隙受累无关。bcl-2阴性肿瘤患者的五年生存率为34%，bcl-2阳性肿瘤患者为71%。在多元回归分析（Cox比例风险模型）中，bcl-2表达和血管浸润是总生存的独立预测因素。
bcl-2表达似乎与早期宫颈癌侵袭性较低的行为相关。向bcl-2非依赖性的转变可能在肿瘤进展中起重要作用。
